Sengenics has largely focused its full-length folded protein arrays technology on research into cancer and autoimmune and infectious disease including COVID-19.
The deals give 10x Genomics control of a combined 110 patents covering in situ analysis methods that the firm says will complement its existing platforms.
The company expects that Blueprint's informatics capabilities in particular will improve variant interpretation and reporting across all its genetic test offerings.
Abcam said that acquisition will help it build out a discovery engine for developing novel edited cell lines and support its knockout validation initiative.
